MedTrace Logo

Once-daily Fluorometholone vs Twice-daily Cyclosporine in Dry Eye Disease

NCT06876116 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2025-03-14

No results posted yet for this study

Summary

This study compares the therapeutic effects of once-daily fluorometholone 0.1% versus twice-daily cyclosporine 0.05% after short-term fluorometholone induction treatment in dry eye disease.

Conditions

  • Dry Eye Disease (DED)

Interventions

DRUG

Fluorometholone 0.1% ophthalmic solution

After induction therapy with fluorometholone 0.1% four times a day for 4 weeks, patients continued with fluorometholone 0.1% once a day for 8 weeks.

DRUG

Cyclosporine 0.05% eye drops

After induction therapy with fluorometholone 0.1% four times a day for 4 weeks, patients continued with cyclosporine 0.05% twice a day for 8 weeks.

Sponsors & Collaborators

  • Taejoon Pharmaceutical Co., Ltd.

    collaborator INDUSTRY

  • Korea University Anam Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-01
Primary Completion
2024-03-01
Completion
2024-05-24

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06876116 on ClinicalTrials.gov